Last reviewed · How we verify
Taclonex Ointment and Hydrogel Patch
Taclonex combines calcipotriene (vitamin D analog) and betamethasone dipropionate (corticosteroid) to reduce inflammation and normalize skin cell differentiation in psoriasis.
Taclonex combines calcipotriene (vitamin D analog) and betamethasone dipropionate (corticosteroid) to reduce inflammation and normalize skin cell differentiation in psoriasis. Used for Plaque psoriasis (topical treatment).
At a glance
| Generic name | Taclonex Ointment and Hydrogel Patch |
|---|---|
| Sponsor | University of California, San Francisco |
| Drug class | Combination topical agent (vitamin D analog + corticosteroid) |
| Target | Vitamin D receptor (VDR) and glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Calcipotriene acts as a vitamin D receptor agonist that promotes keratinocyte differentiation and reduces proliferation, while betamethasone dipropionate provides potent anti-inflammatory effects through glucocorticoid receptor activation. Together, these agents work synergistically to reduce erythema, scaling, and plaque formation characteristic of psoriasis. The ointment and hydrogel patch formulations provide different delivery mechanisms for topical application.
Approved indications
- Plaque psoriasis (topical treatment)
Common side effects
- Skin irritation or burning at application site
- Pruritus
- Skin atrophy (with prolonged use)
- Folliculitis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: